ADMA CEO's Planned Stock Sale Nets 285% Gain While Maintaining 3.7M Share Position
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ADMA Biologics (ADMA) President and CEO Adam S. Grossman reported multiple transactions on June 16, 2025, executed under a pre-established Rule 10b5-1 trading plan from December 2024. The transactions included:
- Exercise of stock options for 15,000 shares at $5.40 per share
- Sale of 21,000 total shares at $20.81 per share
- Post-transaction direct ownership of 2,043,850 shares
- Indirect ownership of 1,143,426 shares through Areth LLC and 580,957 shares through Hariden LLC
Grossman maintains significant equity positions including unvested RSUs totaling over 1 million shares granted between 2022-2025, vesting quarterly over four years. He also holds 810,950 stock options granted February 2024 at $5.40/share, vesting through February 2028. The transactions demonstrate a routine exercise-and-sell pattern while maintaining substantial long-term ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 21,000 shares ($437,010)
Net Sell
6 txns
Insider
Grossman Adam S
Role
President and CEO
Sold
21,000 shs ($437K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 15,000 | $5.40 | $81K |
| Sale | Common Stock | 15,000 | $20.81 | $312K |
| Sale | Common Stock | 6,000 | $20.81 | $125K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 810,950 shares (Direct);
Common Stock — 2,064,850 shares (Direct);
Common Stock — 1,143,426 shares (Indirect, See Footnote)
Footnotes (1)
- Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer. The price reported in Column 4 is the price at which the shares were sold. Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,011,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
FAQ
What insider transactions did ADMA's CEO Adam Grossman report on June 16, 2025?
On June 16, 2025, ADMA's CEO Adam Grossman exercised 15,000 stock options at $5.40 per share and subsequently sold 21,000 shares total (15,000 + 6,000) at $20.81 per share. These transactions were executed pursuant to a Rule 10b5-1 trading plan established on December 5, 2024.
What is the vesting schedule for ADMA CEO's recent stock option grant?
The stock option granted on February 26, 2024, vests over four years with 25% (217,737 shares) vesting on February 26, 2025, and the remaining 75% vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
How many unvested RSUs does ADMA's CEO currently hold?
The CEO holds several RSU grants totaling 1,032,166 unvested units: 252,022 RSUs granted February 2025, 418,296 RSUs from February 2024, 286,848 RSUs from March 2023, and 75,000 RSUs from March 2022. All RSUs vest quarterly over four years from their grant dates.